Sakata Y, Fukushi G, Tsushima K, Suzuki H, Kimura T, Kimura M, Tamura Y, Kishibe T, Saitoh S, Itoh T
1st Dept. of Internal Medicine, Hirosaki University School of Medicine.
Gan To Kagaku Ryoho. 1988 Sep;15(9):2731-5.
Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT. MQF-OK therapy was administered according to our original method. FT and UFT were orally given in a dose of 600-800 mg/body/day and 300-400 mg/body/day, respectively. Three with gallbladder cancer and one with bile duct cancer showed PR. Myelosuppression was observed in all cases, but recovered in two weeks after MQF therapy. We recommend the further trial of MQF-OK therapy plus FT or UFT for gallbladder and bile duct cancer.
4例胆囊癌患者和2例胆管癌患者接受了丝裂霉素C、卡波醌、5-氟尿嘧啶和溶链菌制剂（MQF-OK疗法）联合替加氟（FT）或优福定治疗。MQF-OK疗法按照我们原来的方法给药。FT和优福定分别以600-800mg/体/天和300-400mg/体/天的剂量口服。3例胆囊癌患者和1例胆管癌患者显示部分缓解。所有病例均观察到骨髓抑制，但在MQF治疗后两周恢复。我们建议对胆囊癌和胆管癌进一步试验MQF-OK疗法联合FT或优福定。
